Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fluorodeoxyglucose F18 | 8 | 2020 | 191 | 2.160 |
Why?
|
| Lung Neoplasms | 6 | 2020 | 600 | 1.440 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 459 | 0.910 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2020 | 27 | 0.790 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 20 | 0.670 |
Why?
|
| Thyroiditis | 1 | 2018 | 2 | 0.620 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2018 | 41 | 0.590 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 92 | 0.580 |
Why?
|
| Immunotherapy | 1 | 2018 | 237 | 0.520 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 402 | 0.450 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 489 | 0.420 |
Why?
|
| Brain | 2 | 2020 | 1313 | 0.380 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1173 | 0.340 |
Why?
|
| Radiopharmaceuticals | 4 | 2022 | 205 | 0.260 |
Why?
|
| Brain Neoplasms | 2 | 2020 | 282 | 0.250 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 3132 | 0.200 |
Why?
|
| Artifacts | 2 | 2018 | 53 | 0.180 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 288 | 0.180 |
Why?
|
| Middle Aged | 4 | 2018 | 12258 | 0.170 |
Why?
|
| Nortropanes | 1 | 2018 | 2 | 0.160 |
Why?
|
| Eosinophilic Granuloma | 1 | 2018 | 3 | 0.160 |
Why?
|
| Male | 7 | 2022 | 25439 | 0.150 |
Why?
|
| Amyloid beta-Peptides | 1 | 2018 | 57 | 0.150 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 390 | 0.150 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2018 | 51 | 0.150 |
Why?
|
| Biological Transport | 1 | 2018 | 170 | 0.150 |
Why?
|
| Hypothalamus | 1 | 2018 | 44 | 0.150 |
Why?
|
| Humans | 11 | 2022 | 49863 | 0.150 |
Why?
|
| Amyloidosis | 1 | 2018 | 77 | 0.150 |
Why?
|
| Cryosurgery | 1 | 2018 | 35 | 0.150 |
Why?
|
| Aged | 4 | 2018 | 9434 | 0.150 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2018 | 52 | 0.150 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 235 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 242 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 225 | 0.130 |
Why?
|
| Parkinson Disease | 1 | 2018 | 141 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2018 | 6106 | 0.130 |
Why?
|
| Disease Progression | 1 | 2018 | 822 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 153 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2018 | 282 | 0.120 |
Why?
|
| Female | 4 | 2018 | 26520 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 329 | 0.110 |
Why?
|
| Prognosis | 1 | 2018 | 1948 | 0.110 |
Why?
|
| Radioisotopes | 1 | 2022 | 17 | 0.050 |
Why?
|
| Adult | 1 | 2018 | 13325 | 0.050 |
Why?
|
| Fluorine Radioisotopes | 1 | 2018 | 24 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 700 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2018 | 60 | 0.040 |
Why?
|
| Arizona | 1 | 2017 | 12 | 0.040 |
Why?
|
| Software | 1 | 2018 | 273 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 607 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1129 | 0.030 |
Why?
|
| Algorithms | 1 | 2018 | 613 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 855 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 982 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 1180 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 1526 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 3597 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 4013 | 0.020 |
Why?
|